Our Portfolio

KBI Biopharma Inc.

Outline Biopharmaceutical contract analytical/process development/manufacturing services for large pharmaceutical companies and biotechnology companies
Website

http://www.kbibiopharma.com/

Industry Health/medicine
Commercialization stage Utilization of overseas management resources

Provided Support

  • Enhance the biopharmaceutical industry in Japan/Asia through the further expansion of currently the US/Europe-focused KBI’s business into Japan/Asia, with the acquisition of cutting-edge U.S. technology and expertise in the development and manufacturing of biopharmaceuticals such as antibodies
  • Drive biopharmaceutical drug discovery by establishing a value chain from research, development, and manufacturing, combined with INCJ’s network of Japanese biotechnology companies and small- and medium-sized pharmaceutical companies
Authorized Investment US$50 million (maximum)
Announcement Date Feb 26, 2015 / Dec 08, 2016
Investment Structure

Related Press Releases

Dec 08, 2016
INCJ to sell its shares in KBI Biopharma, Inc.
Feb 26, 2015
INCJ, JSR Corporation, and CMIC Holdings Co., Ltd. acquire U.S. biopharmaceutical contract development and manufacturer KBI Biopharma, Inc.
HOME
About Us
Our Business
Newsroom
Our Investments